Half-year report · HY

Period2025-07-01 → 2025-12-31
Filed2026-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥2.4bn2025-07-01 → 2025-12-31Cons.Net sales
Revenue¥4.8bn2024-07-01 → 2025-06-30Cons.Net sales (5-year summary)
Revenue¥2.7bn2024-07-01 → 2024-12-31Cons.Net sales
Operating income¥231m2025-07-01 → 2025-12-31Cons.Operating income
Operating income−¥203m2024-07-01 → 2024-12-31Cons.Operating income
Ordinary income¥238m2025-07-01 → 2025-12-31Cons.Ordinary income
Ordinary income−¥129m2024-07-01 → 2025-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income−¥198m2024-07-01 → 2024-12-31Cons.Ordinary income
Profit before tax¥195m2025-07-01 → 2025-12-31Cons.Income before income taxes
Profit before tax−¥212m2024-07-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)¥162m2025-07-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥211m2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥222m2024-07-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income¥162m2025-07-01 → 2025-12-31Cons.Profit loss
Net income−¥222m2024-07-01 → 2024-12-31Cons.Profit loss
Total assets¥6.7bnat 2025-12-31Cons.Assets
Total assets¥6.8bnat 2025-06-30Cons.Assets
Total assets¥6.6bnat 2024-12-31Cons.Total assets (5-year summary)
Total liabilities¥612mat 2025-12-31Cons.Liabilities
Total liabilities¥775mat 2025-06-30Cons.Liabilities
Net assets / equity¥6.1bnat 2025-12-31Cons.Net assets
Net assets / equity¥6.0bnat 2025-06-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-12-31Cons.Net assets (5-year summary)
Cash and deposits¥5.0bnat 2025-12-31Cons.Cash and deposits
Cash and deposits¥5.0bnat 2025-06-30Cons.Cash and deposits
Cash & equivalents¥5.0bnat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.0bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.8bnat 2024-06-30vCons.Cash and cash equivalents
Operating cash flow¥134m2025-07-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥558m2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥98m2024-07-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Investing cash flow¥71m2025-07-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥389m2024-07-01 → 2025-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥324m2024-07-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥139m2025-07-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥214,0002024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥172,0002024-07-01 → 2024-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥6.192025-07-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.052024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.52024-07-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio90.8%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.4%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio91.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 51
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-07-01 → 2025-12-31−¥16m
Reconciling Itemsreconcilingrevenue external2025-07-01 → 2025-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2025-07-01 → 2025-12-31−¥17m
Reconciling Itemsreconcilingsegment profit2025-07-01 → 2025-12-31−¥174m
Clinical Evidence Servicereportable segmentrevenue2025-07-01 → 2025-12-31¥131m
Clinical Evidence Servicereportable segmentrevenue external2025-07-01 → 2025-12-31¥131m
Clinical Evidence Servicereportable segmentsegment profit2025-07-01 → 2025-12-31¥11m
Functional Cosmetic Retailingreportable segmentrevenue2025-07-01 → 2025-12-31¥726m
Functional Cosmetic Retailingreportable segmentrevenue external2025-07-01 → 2025-12-31¥725m
Functional Cosmetic Retailingreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥919,000
Functional Cosmetic Retailingreportable segmentsegment profit2025-07-01 → 2025-12-31¥83m
Functional Food Retailingreportable segmentrevenue2025-07-01 → 2025-12-31¥933m
Functional Food Retailingreportable segmentrevenue external2025-07-01 → 2025-12-31¥926m
Functional Food Retailingreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥7m
Functional Food Retailingreportable segmentsegment profit2025-07-01 → 2025-12-31¥217m
Functional Material Developmentreportable segmentrevenue2025-07-01 → 2025-12-31¥180m
Functional Material Developmentreportable segmentrevenue external2025-07-01 → 2025-12-31¥171m
Functional Material Developmentreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥9m
Functional Material Developmentreportable segmentsegment profit2025-07-01 → 2025-12-31¥19m
Health Care Support Servicereportable segmentrevenue2025-07-01 → 2025-12-31¥460m
Health Care Support Servicereportable segmentrevenue external2025-07-01 → 2025-12-31¥460m
Health Care Support Servicereportable segmentsegment profit2025-07-01 → 2025-12-31¥75m
—segment totalrevenue2025-07-01 → 2025-12-31¥2.4bn
—segment totalrevenue external2025-07-01 → 2025-12-31¥2.4bn
—segment totalrevenue intersegment2025-07-01 → 2025-12-31¥17m
—segment totalsegment profit2025-07-01 → 2025-12-31¥404m
Reconciling Itemsreconcilingrevenue2024-07-01 → 2024-12-31−¥14m
Reconciling Itemsreconcilingrevenue external2024-07-01 → 2024-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2024-12-31−¥15m
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2024-12-31−¥159m
Clinical Evidence Servicereportable segmentrevenue2024-07-01 → 2024-12-31¥152m
Clinical Evidence Servicereportable segmentrevenue external2024-07-01 → 2024-12-31¥152m
Clinical Evidence Servicereportable segmentsegment profit2024-07-01 → 2024-12-31¥19m
Functional Cosmetic Retailingreportable segmentrevenue2024-07-01 → 2024-12-31¥751m
Functional Cosmetic Retailingreportable segmentrevenue external2024-07-01 → 2024-12-31¥751m
Functional Cosmetic Retailingreportable segmentsegment profit2024-07-01 → 2024-12-31¥25m
Functional Food Retailingreportable segmentrevenue2024-07-01 → 2024-12-31¥1.2bn
Functional Food Retailingreportable segmentrevenue external2024-07-01 → 2024-12-31¥1.2bn
Functional Food Retailingreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥4m
Functional Food Retailingreportable segmentsegment profit2024-07-01 → 2024-12-31−¥132m
Functional Material Developmentreportable segmentrevenue2024-07-01 → 2024-12-31¥183m
Functional Material Developmentreportable segmentrevenue external2024-07-01 → 2024-12-31¥173m
Functional Material Developmentreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥11m
Functional Material Developmentreportable segmentsegment profit2024-07-01 → 2024-12-31¥3m
Health Care Support Servicereportable segmentrevenue2024-07-01 → 2024-12-31¥393m
Health Care Support Servicereportable segmentrevenue external2024-07-01 → 2024-12-31¥393m
Health Care Support Servicereportable segmentsegment profit2024-07-01 → 2024-12-31¥39m
—segment totalrevenue2024-07-01 → 2024-12-31¥2.7bn
—segment totalrevenue external2024-07-01 → 2024-12-31¥2.7bn
—segment totalrevenue intersegment2024-07-01 → 2024-12-31¥15m
—segment totalsegment profit2024-07-01 → 2024-12-31−¥45m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 465
ItemContextValueUnit
Number of shares heldInterimInstant_No2MajorShareholdersMember4426800
Shareholding ratioInterimInstant_No2MajorShareholdersMember0.1692
Number of shares heldInterimInstant_No3MajorShareholdersMember901200
Shareholding ratioInterimInstant_No3MajorShareholdersMember0.0345
Number of shares heldInterimInstant_No4MajorShareholdersMember455700
Shareholding ratioInterimInstant_No4MajorShareholdersMember0.0174
Number of shares heldInterimInstant_No5MajorShareholdersMember352000
Shareholding ratioInterimInstant_No5MajorShareholdersMember0.0135
Number of shares heldInterimInstant_No6MajorShareholdersMember337800
Shareholding ratioInterimInstant_No6MajorShareholdersMember0.0129
Number of shares heldInterimInstant_No7MajorShareholdersMember320000
Shareholding ratioInterimInstant_No7MajorShareholdersMember0.0122
Number of shares heldInterimInstant_No8MajorShareholdersMember275000
Shareholding ratioInterimInstant_No8MajorShareholdersMember0.0105
Number of shares heldInterimInstant_No9MajorShareholdersMember220000
Shareholding ratioInterimInstant_No9MajorShareholdersMember0.0084
Number of shares heldInterimInstant_No10MajorShareholdersMember204800
Shareholding ratioInterimInstant_No10MajorShareholdersMember0.0078
Number of shares heldInterimInstant12118900
Shareholding ratioInterimInstant0.4633
Number of shares issued shares voting rightsInterimInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsInterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember26147300
Number of voting rights issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember261473
Number of shares issued shares voting rightsInterimInstant_OrdinarySharesSharesLessThanOneUnitMember10900
Number of shares issued shares voting rightsInterimInstant26158200
Number of voting rights issued shares voting rightsInterimInstant261473
Cash and depositsPrior1YearInstant4958351000JPY
Cash and depositsInterimInstant5024090000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant223883000JPY
Notes and accounts receivable trade and contract assetsInterimInstant284040000JPY
Short term investment securitiesPrior1YearInstant300000000JPY
Short term investment securitiesInterimInstant300000000JPY
MerchandisePrior1YearInstant369947000JPY
MerchandiseInterimInstant338222000JPY
Work in processPrior1YearInstant216275000JPY
Work in processInterimInstant226888000JPY
Raw materials and suppliesPrior1YearInstant340293000JPY
Raw materials and suppliesInterimInstant175455000JPY
Other caPrior1YearInstant188695000JPY
Other caInterimInstant92712000JPY
Allowance for doubtful accounts caPrior1YearInstant-144000JPY
Allowance for doubtful accounts caInterimInstant-4000JPY
Current assetsPrior1YearInstant6597302000JPY
Current assetsInterimInstant6441406000JPY
Property plant and equipmentPrior1YearInstant9601000JPY
Property plant and equipmentInterimInstant41463000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-06-30pass rounding
balance sheet identityconsolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-07-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-07-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-07-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-07-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass